Zadaxin

DRUG2 trials

Sponsors

Replicor Inc., Shanghai Public Health Clinical Center

Conditions

HIV-1-infectionHepatitis B, Chronic

Early Phase 1

Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder

CompletedNCT04963712

Shanghai Public Health Clinical CenterHIV-1-infection

Start: 2021-09-01End: 2022-08-11Updated: 2023-07-18

Phase 1

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

CompletedNCT02646189

Replicor Inc.Hepatitis B, Chronic

Start: 2011-08-31End: 2013-08-31Updated: 2016-01-05

Related Papers

Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV.

2024-01-177 citations

Kinetics of hepatitis B surface antigen quasispecies during REP 2139‐Ca therapy in HBeAg‐positive chronic HBV infection

Journal of Viral Hepatitis2019-07-199 citations

Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol

Zeitschrift für Gastroenterologie2019-01-01

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

PLoS ONE2016-06-03176 citations